Effectiveness studies: Advantages and disadvantages

Dialogues in Clinical Neuroscience

Volumn 13, Issue 2, 2011, Pages 199-207

  Möller, Hans Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic; Effectiveness study; First generation antipsychotic (FGA); Real world study; Second generation antipsychotic (SGA)

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; HUMAN; INFORMATION PROCESSING; METHODOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; CLINICAL TRIAL (TOPIC); ECONOMICS; EPIDEMIOLOGY; MEDICAL RESEARCH; MENTAL DISEASE; REVIEW; TREATMENT OUTCOME;

NEUROLEPTIC AGENT;

ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CONFOUNDING FACTORS (EPIDEMIOLOGY); EVIDENCE-BASED MEDICINE; HUMANS; MENTAL DISORDERS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 80052140226     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Möller HJ, Maier W Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci. 2010;260:25-39.
2. Kunz R, Vist G, Oxman A Randomisation to protect against selection bias in healthcare trials. Cochrane Database Syst Rev. 2007:MR000012
3. Möller HJ, Broich K Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci. 2010;260:3-16.
4. Campbell M, Fitzpatrick R, Haines A, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321:694-696.
5. Eccles M, Grimshaw J, Campbell M, Ramsay C Research designs for studies evaluating the effectiveness of change and improvement strategies. Qual Saf Health Care. 2003;12:47-52.
6. Möller HJ Do effectiveness ("real world") studies on antipsychotics tell us the real truth? Eur Arch Psychiatry Clin Neurosci. 2008;258:257-270.
7. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005;30:445-460.
8. Tunis SR, Stryer DB, Clancy CM Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA. 2003;290:1624-1632.
9. Khan A Suicide rates of clinical trials of SSRIs, other antidepressants and placebo: analysis of FDA reports. Am J Psychiatry. 2003;160:790-792.
10. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
11. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on clinical investigation of medicinal products in the treatment of depression. Available at: http://www.emea.eu.int.
12. Ascher-Svanum H, Zhu B, Faries D, Ernst FR A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia. Ann Gen Hosp Psychiatry. 2004;3:11.
13. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry. 2006;6:8.
14. Dossenbach M, Erol A, el Mahfoud Kessaci M, et al. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. J Clin Psychiatry. 2004;65:312-321.
15. Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) Study: rationale, methods and recruitment. Acta PsychiatrScand. 2003;107:222-232.
16. Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol. 2007;17:235-244.
17. Möller HJ, Langer S, Schmauss M Escitalopram in clinical practice: results of an open-label trial in outpatients with depression in a naturalistic setting in Germany. Pharmacopsychiatry. 2007;40:53-57.
18. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119-142.
19. Sheehan DV, Keene MS, Eaddy M, Krulewicz S, Kraus JE, Carpenter DJ Differences in medication adherence and healthcare resource utilization patterns, older versus newer antidepressant agents in patients with depression and/or anxiety disorders. CNS Drugs. 2008;22:963-973.
20. Adam D, Kasper S, Möller HJ, Singer EA Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. Eur Arch Psychiatry Clin Neurosci. 2005;255:258-260.
21. Baldwin D, Broich K, Fritze J, Kasper S, Westenberg H, Möller HJ Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci. 2003;253:22-28.
22. Möller HJ Sind placebokontrollierte Studien zum Wirksamkeitsbeweis von Antidepressiva notwendig? Nervenarzt. 2004;5:421-424.
23. Möller HJ Plazebo-kontrollierte Studien zum Wirkungsnachweis von Antidepressiva sind notwendig! Psychopharmakotherapie. 2003;10: 85-86.
24. Möller HJ Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al, 2008. Eur Arch Psychiatry Clin Neurosci. 2008;258:451-455.
25. Buckley PF Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry. 2007;68(suppl 6):5-9.
26. Weiden PJ Discontinuing and switching antipsychotic medications: understanding the CATIE schizophrenia trial. J Clin Psychiatry. 2007;68(suppl 1):12-9.
27. Weiden PJ Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol. 2006;20:104-118.
28. IMaber D Subjective effects of antipsychotic treatment. Acta Psychiatr Scand. 2005;111:81-83.
29. Karow A, Naber D Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berfj. 2002;162:3-10.
30. Lambert M, Naber D Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs. 2004;18(suppl 2):5-17.
31. Ware JE, Jr. Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
32. Ware JE, Snow KK, Kosinski M, Gandek B SF-36 Health Survey Manual and Interpretation Guide. 1993
33. Pukrop R, Schlaak V, Möller-Leimkühler AM, et al. Reliability and validity of quality of life assessed by the Short-Form 36 and the Modular System of Quality of Life in patients with schizophrenia and patients with depression. Psych Res. 2003;119:63-79.
34. Pukrop R, Möller HJ, Steinmeyer EM Quality of life in psychiatry: a systematic contribution to construct validation and the development of the integrative assessment tool "modular system for quality of life" Eur Arch Psychiatry Clin Neurosci. 2000;250:120-132.
35. Cramer JA, Rosenheck R, Xu W, Thomas J, Henderson W, Charney DS Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull. 2000;26:659-666.
36. Möller HJ Rating depressed patients: observer- vs self-assessment. Eur Psychiatry. 2000;15:160-172.
37. Möller HJ Standardised rating scales in psychiatry: Methodological basis, possibilities, limitations and descriptions of important rating scales. World J Biol Psychiatry. 2009;10:6-26.
38. Paykel ES, Norton KRW Self-report and clinical interview in the assessment of depression. In: Sartorius N, Ban TA, eds. Assessment of Depression. 1986:356-366.
39. Phillips GA, Van Brunt DL, Roychowdhury SM, Xu W, Naber D The relationship between quality of life and clinical efficacy from a randomized trial comparing olanzapine and ziprasidone. J Clin Psychiatry. 2006;67:1397-1403.
40. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatry. 1999;60(suppl 19):38-45.
41. Franz M, Lis S, Pluddemann K, Gallhofer B Conventional versus atypical neuroleptics: subjective quality of life in schizophrenic patients. Br J Psychiatry. 1997;170:422-425.
42. Awad AG, Voruganti LN New antipsychotics, compliance, quality of life, and subjective tolerability - are patients better off? Can J Psychiatry. 2004;49:297-302.
43. Pyne JM, Sullivan G, Kaplan R, Williams DK Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care. 2003;41:208-217.
44. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290:2693-2702.
45. Hofer A, Hummer M, Huber R, Kurz M, Walch T, Fleischhacker WW Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol. 2000;20:699-702.
46. Meltzer HY, Bobo WV Interpreting the efficacy findings in the CATIE study: what clinicians should know. CNS Spectr. 2006;11(7 Suppl 7):14-24.
47. Möller HJ Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry. 2009;10:180-195.
48. Möller HJ Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatry Clin Neurosci. 2005;255:371-372.
49. Kasper S, Winkler D Addressing the limitations of the CATIE study. World J Biol Psychiatry. 2006;7:126-127.
50. Tandon R, Möller HJ, Belmaker RH, et al. World Psychiatric Association Pharmacopsychiatry Section Statement on Comparative Effectiveness of Antipsychotics in the Treatment of Schizophrenia. Schizophr Res. 2007;2008:100:20-38.
51. Adli M, Bauer M, Rush AJ Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry. 2006;59:1029-1038.
52. Bauer M, Pfennig A, Linden M, Smolka MN, Neu P, Adli M Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression. J Clin Psychopharmacol. 2009;29:327-333.
53. Rush AJ STAR*D: what have we learned? Am J Psychiatry. 2007;164:201-204.
54. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
55. Seemüller F, Möller HJ, Obermeier M, et al. Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials. J Clin Psychiatry. 2010;71:1426-1433.
56. Zimmermann M, Chelminski I, Posternak MA Generlisability of antidepressants efficacy trials: differences between depressed psychiatric outpatiens who would or would not qualify for an efficacy trial. Am J Psychiatry. 2005;162:1370-1372.